Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Replimune (Nasdaq: REPL) said company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.
A simultaneous webcast will be available in the Investors section of replimune.com, and a replay will be available for 30 days following the conference.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, REPL gained 0.31%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
REPL was up 0.52% pre-news while several biotech peers (e.g., BCYC -5.18%, NBTX -5.63%, RGNX -6.4%) traded lower, indicating stock-specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 07 | Clinical data update | Positive | +4.8% | Updated RP1 plus nivolumab data with ORR and durable responses at SITC 2025. |
| Nov 06 | Earnings and update | Positive | -0.9% | Fiscal Q2 results and FDA acceptance of RP1 BLA resubmission with set PDUFA date. |
| Oct 20 | Regulatory milestone | Positive | +98.8% | FDA acceptance of RP1 BLA resubmission for advanced melanoma with PDUFA date. |
| Sep 18 | Regulatory update | Negative | -39.4% | Type A meeting feedback on CRL, with path under accelerated approval undetermined. |
| Sep 02 | Meeting scheduled | Negative | +9.3% | Scheduling Type A meeting and warning RP1 program viability without accelerated approval. |
Recent news flow shows strong price sensitivity to FDA and RP1 regulatory milestones, with mixed reactions to clinical data and earnings updates.
Over the last few months, REPL’s trajectory has been driven by RP1 regulatory milestones and supporting data. On Sep 2, 2025 and Sep 18, 2025, Type A meeting communications and FDA feedback on the CRL highlighted uncertainty for accelerated approval. Sentiment shifted sharply on Oct 20, 2025 when the FDA accepted the BLA resubmission with a PDUFA date of April 10, 2026, followed by confirmation in the 10-Q and fiscal Q2 update. The Nov 7, 2025 SITC data for RP1 plus nivolumab further reinforced durability signals. Today’s J.P. Morgan conference appearance fits into this ongoing communication cadence without adding new clinical or regulatory data.
Regulatory & Risk Context
An effective shelf registration amendment filed on Nov 6, 2025 allows Replimune to offer up to $250,000,000 of securities, including an at-the-market program of up to $100,000,000 of common stock within that total, providing flexibility to raise capital over time.
Market Pulse Summary
This announcement highlights Replimune’s upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2025, giving management a forum to discuss its oncolytic immunotherapy pipeline and RP1 regulatory path. In recent months, key milestones have included FDA acceptance of the RP1 BLA resubmission with an April 10, 2026 PDUFA date and updated RP1 data. Investors may watch for any new strategic or clinical color provided during the conference webcast and subsequent replay.
Key Terms
oncolytic immunotherapies medical
AI-generated analysis. Not financial advice.
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.
A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
When will Replimune (REPL) present at the J.P. Morgan Healthcare Conference?
How can investors watch the Replimune (REPL) presentation on January 14, 2025?
Will there be a replay of Replimune's (REPL) J.P. Morgan presentation and for how long?
What topics will Replimune (REPL) management cover at the JP Morgan conference?
Where can I find the webcast link for Replimune (REPL)'s January 14, 2025 presentation?
